Eurofins Achieves 48% Revenue Growth and over 10% Organic Growth in Q1 2016
2016年4月25日 - 2:30PM
ビジネスワイヤ(英語)
- Q1 revenues increased 48% year-on-year
to EUR 582m
- Organic growth of over 10% in the first
quarter, following a strong organic growth of over 9.5% in the
final quarter of 2015, confirms the positive outlook as
communicated in November 20151.
- Strong growth in the US (up over 41% at
constant exchange rates), which made up nearly one-third of total
Group revenues during the quarter, as tailwinds accelerate and
rapid expansion continues.
- Growth trends remain positive in most
of Eurofins’ businesses and geographies.
Regulatory News:
Eurofins (Paris:ERF):
Comments from the CEO, Dr. Gilles Martin: “The Group’s
performance in the first quarter validates the optimism expressed
by our leaders during our most recent budget cycle as communicated
in our press release of November 24, 2015. These results
demonstrate that we are off to a good start to achieve our
objective of generating EUR 2.5bn of revenues in 2016. Continued
strengthening in the underlying trends in most of our businesses,
as well as the benefits that we are starting to see from our
network investments, reinforce our confidence in our ability to
execute on our mid-term objective of doubling in size again to
reach revenues of EUR 4bn and adjusted EBITDA of EUR 800m by
2020.”
EUR m
Q1 2016
Q1 2015 % Growth of which organic of
which FX
Eurofins Group Revenues 582
394 48% >10% 0.1%
Eurofins generated robust growth rates across most of its
geographies. In the first quarter, the Group achieved revenues of
EUR 582m, representing growth of about 48% over Q1 2015, over 10%
of which was organic. The remainder of the revenue growth was made
up of contribution from acquisitions, with neutral currency impact
during the quarter.
The US (32% of Group revenues in Q1) continues to generate
organic growth well above Group average on strongly positive trends
notably in biopharmaceutical testing, as well as strong growth in
specialty clinical diagnostics. In France, which now makes up 26%
of total revenues following the acquisition of BioAccess and
Biomnis in the second half of last year, the food testing business,
as well as most areas of environment testing, delivered organic
growth above Group objective. Eurofins’ third largest market,
Germany (11% of Group revenues), also generated very strong organic
growth despite the mature local testing market as the Group
continues to win market share. Most of the Group’s businesses in
the geographies where it is present continue to deliver robust
growth as we develop our footprint and benefit from our ongoing
investments.
Overall, the strong performance in a seasonally weaker first
quarter allows the Group to remain very positive about its
medium-term outlook.
Organic growth for a given period (Q1, Q2, Q3, Half Year, Nine
Months or Full Year) - non-IFRS measure calculating the growth in
revenues during that period between 2 successive years for the same
scope of businesses using the same exchange rates but excluding
discontinued operations.
For the purpose of organic growth calculation for year Y, the
relevant scope used is the scope of businesses that have been
consolidated in the Group's income statement of the previous
financial year (Y-1). Revenue contribution from companies acquired
in the course of Y-1 but not consolidated for the full year are
adjusted as if they had been consolidated as from 1st January Y-1.
All revenues from businesses acquired since 1st January Y are
excluded from the calculation.
For more information, please visit
www.eurofins.com.
Notes for the editor:
Eurofins – a global leader in bio-analysis
Eurofins Scientific believes it is the world leader in food,
environment and pharmaceutical products testing, as well as one of
the global market leaders in agroscience, genomics, discovery
pharmacology and central laboratory services. In addition, Eurofins
is one of the key emerging players in specialty clinical diagnostic
testing in Europe and the USA.
With over 23,000 staff in more than 225 laboratories across 39
countries, Eurofins offers a portfolio of over 130,000 validated
analytical methods for evaluating the safety, identity,
composition, authenticity, origin, traceability and purity of
biological substances and products, as well as for innovative
clinical diagnostic. The Group provides its customers with
high-quality services, accurate results on time and expert advice
by its highly qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by
expanding both its technology portfolio and its geographic reach.
Through R&D and acquisitions, the Group draws on the latest
developments in the field of biotechnology and analytical chemistry
to offer its clients unique analytical solutions and the most
comprehensive range of testing methods.
As one of the most innovative and quality oriented international
players in its industry, Eurofins is ideally positioned to support
its clients’ increasingly stringent quality and safety standards
and the expanding demands of regulatory authorities and healthcare
practitioners around the world.
The shares of Eurofins Scientific are listed on the Euronext
Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg
ERF FP).
Important disclaimer:
This press release contains forward-looking statements and
estimates that involve risks and uncertainties. The forward-looking
statements and estimates contained herein represent the judgement
of Eurofins Scientific’ management as of the date of this release.
These forward-looking statements are not guarantees for future
performance, and the forward-looking events discussed in this
release may not occur. Eurofins Scientific disclaims any intent or
obligation to update any of these forward-looking statements and
estimates. All statements and estimates are made based on the
information available to the Company’s management as of the date of
publication, but no guarantee can be made as to their validity.
1 Eurofins Scientific Press Release 24 November 2015.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160424005034/en/
Eurofins Investor Relations+32-2-766 1620ir@eurofins.com
Enerplus (NYSE:ERF)
過去 株価チャート
から 9 2024 まで 10 2024
Enerplus (NYSE:ERF)
過去 株価チャート
から 10 2023 まで 10 2024